Drug Trial Radar · NCT01141452
Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD
Last checked: Nov 19, 2026Latest source record: Mar 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
815,377
Actual
Start
Jan 2001
Primary completion
Jun 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- Research in Real-Life LtdResearch network
- Sponsor type
- Research network
- Collaborators
- Teva Branded Pharmaceutical Products R&D, Inc.
- First posted
- Jun 10, 2010
Design
- Study type
- Observational
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing chronic obstructive pulmonary disease (COPD) in primary care patients with evidence of COPD who either initiate inhaled corticosteroid (ICS) therapy, or have an increase in their ICS dose, as hydrofluoroalkane (HFA) beclometasone dipropionate (BDP) (hereafter Qvar®), CFC-BDP (hereafter BDP) and fluticasone propionate (FP) via pressurised metered-dose inhalers.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Extra-fine hydrofluoroalkane beclomethasone MDIDrug
Step-up in baseline BDP-equivalent ICS dose
Chlorofluorocarbon beclomethasone metered dose inhalerDrug
Step-up in baseline BDP-equivalent ICS dose
Fluticasone propionate metred dose inhalerDrug
Step-up in baseline BDP-equivalent ICS dose
Fluticasone propionate metred dose inhalerDrug
Initiation of ICS therapy
Hydrofluoroalkane beclomethasone metred dose inhalerDrug
Initiation of ICS therapy
Chlorofluorocarbon beclomethasone dipropionateDrug
Initiation of ICS therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of exacerbations; exacerbation rate ratio; time to first after IPDTime frame: Two-year outcome period
- COPD treatment successTime frame: Two-year outcome period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General Practice Research Database
London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.